Pacer Advisors
ESPR

Pacer Advisors’s Esperion Therapeutics ESPR Stock Holding History

Pacer Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,572
Closed -$72K – 1453
2021
Q1 		$72K Sell
2,572
-1,664
-39% -$49.1K ﹤0.01% 1361
2020
Q4 		$110K Buy
4,236
+1,820
+75% +$54.5K ﹤0.01% 1352
2020
Q3 		$90K Buy
+2,416
New +$95.7K ﹤0.01% 1264
2018
Q4 		– Sell
-5,090
Closed -$226K – 707
2018
Q3 		$226K Buy
+5,090
New +$234K 0.01% 1007
2018
Q1 		– Sell
-1,400
Closed -$92K – 1066
2017
Q4 		$92K Buy
+1,400
New +$75.4K 0.01% 967

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pacer Advisors's ESPR Position: Q2 2021 in Review

Pacer Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 2,572 shares — an estimated $72K sold.

Pacer Advisors first reported a position in ESPR in Q4 2017 and held it in 5 quarters. The position peaked at $226K in Q3 2018. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • Pacer Advisors reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 2,572 Esperion Therapeutics shares in Q2 2021, an estimated $72K.
  • Pacer Advisors first reported a position in Esperion Therapeutics in Q4 2017 and held it in 5 quarters.
  • Pacer Advisors's Esperion Therapeutics position peaked at $226K in Q3 2018.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.